Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data


Creative Commons License

Mauguen A., Pignon J., Burdett S., Domerg C., Fisher D., Paulus R., ...More

LANCET ONCOLOGY, vol.14, pp.619-626, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 14
  • Publication Date: 2013
  • Doi Number: 10.1016/s1470-2045(13)70158-x
  • Journal Name: LANCET ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.619-626
  • Bursa Uludag University Affiliated: Yes

Abstract

Background The gold standard endpoint in clinical trials of chemotherapy and radiotherapy for lung cancer is overall survival. Although reliable and simple to measure, this endpoint takes years to observe. Surrogate endpoints that would enable earlier assessments of treatment effects would be useful. We assessed the correlations between potential surrogate endpoints and overall survival at individual and trial levels.